VistaGen Therapeutics第三季度每股收益$（0.46）击败$（0.51）估计，销售额为23.4万美元，超过180.00万美元估计

VistaGen Therapeutics (NASDAQ: VTGN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 109.09 percent decrease over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $234.00 thousand which beat the analyst consensus estimate of $180.00 thousand by 30.00 percent. This is a 43.12 percent decrease over sales of $411.40 thousand the same period last year.